- Antisense nucleic acid therapeutics, designed to selectively bind to RNA and modulate gene expression, are increasingly vital in modern medicine for their targeted approach in treating genetic disorders, cancers, and viral infections, offering new pathways for personalized and precision therapies
- The escalating demand for antisense therapeutics is primarily fueled by the rise in genetic and rare diseases, advancements in oligonucleotide chemistry, and growing R&D investments by pharmaceutical companies and biotech firms
- North America dominated the antisense nucleic acid therapeutics market with the largest revenue share of 43% in 2024, characterized by robust biopharmaceutical infrastructure, early adoption of gene-targeted therapies, and a high concentration of key market players, with the U.S. witnessing significant progress in clinical trials and regulatory approvals of antisense-based drugs
- Asia-Pacific is expected to be the fastest growing region in the antisense nucleic acid therapeutics market during the forecast period due to expanding healthcare expenditure, increasing government support for genomic research, and a growing pipeline of RNA-based therapies
- Oncology segment dominated the antisense nucleic acid therapeutics market with a market share of 38.2% in 2024, driven by its urgent need for novel cancer treatments, growing prevalence of oncological diseases, and the promising clinical efficacy demonstrated by antisense compounds in cancer gene silencing
